EGFR and non-small cell lung carcinoma: Unfortunately, some NSCLC patients have successively developed secondary EGFR T790M mutations, receptor tyrosine kinase c-MET (MET), and hepatocyte growth factor (HGF) overexpression after receiving long-term treatment, leading to acquired resistance thus limiting the efficacy of EGFR-TKIs (110) (111) (112).